Articles

The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer. Read More ›

• Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
• Lay Navigation Reduces Medicare Costs, Resource Utilization
• Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer

Read More ›

Following a year in which approximately 2 dozen cancer drugs were approved by the FDA, approvals in 2016 decreased by approximately 50% compared with 2015. Read More ›

In recognition of the distress associated with the diagnosis and treatment of cancer, the National Comprehensive Cancer Network (NCCN) has produced several resources to help patients report their distress and cope with it. Read More ›

Adolescents and young adults (AYAs) with cancer often wait too long to discuss their end-of-life preferences, or they do not discuss those preferences at all and pass away in a manner that is against their wishes. Read More ›

Providers caring for dying patients should be prepared to discuss physician-assisted death (PAD). Read More ›

The role of nurse navigators has grown exponentially in recent years, and is now regarded as an integral element of oncology treatment and patient care. The Academy of Oncology Nurse & Patient Navigators (AONN+) defines patient navigation as the “process whereby a patient is given individualized support across the continuum of care, beginning with community outreach to raise awareness and perform cancer screening, through the diagnosis and treatment process, and on to short- and long-term survivorship or end of life.” At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer. Read More ›

Three clinical trials conducted in postmenopausal women with hormone receptor (HR)-positive breast cancer showed no advantage to extending endocrine therapy beyond an initial 5 years. Read More ›

In metastatic hormone receptor (HR)-positive breast cancer, adding everolimus to fulvestrant overcomes resistance to aromatase inhibitor therapy. Read More ›

Updated guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer confirm older conservative guidance. Read More ›